AR003951A1 - SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT. - Google Patents

SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT.

Info

Publication number
AR003951A1
AR003951A1 ARP960102562A AR10256296A AR003951A1 AR 003951 A1 AR003951 A1 AR 003951A1 AR P960102562 A ARP960102562 A AR P960102562A AR 10256296 A AR10256296 A AR 10256296A AR 003951 A1 AR003951 A1 AR 003951A1
Authority
AR
Argentina
Prior art keywords
disease
parkinson
prepare
compositions
treatment
Prior art date
Application number
ARP960102562A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1995/000398 external-priority patent/WO1996037226A2/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR003951A1 publication Critical patent/AR003951A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a una formulación para tratar la Enfermedad de Parkinson en un mamífero que sufre la enfermedad del Parkinson. La formulacióncomprende una combinación de un antagonista de NMDA selectivo para el cerebro anterior y unco mpuesto que es capaz de aumentar la retroalimentaciónexcitadora desde el núcleo ventrolateral del tálamo al cortex. Asimismo se revelan composiciones farmacéuticas que se utilizan para preparar laformulación sinérgica.This invention relates to a formulation for treating Parkinson's disease in a mammal suffering from Parkinson's disease. The formulation comprises a combination of a forebrain selective NMDA antagonist and a compound that is capable of increasing excitatory feedback from the ventrolateral nucleus of the thalamus to the cortex. Also disclosed are pharmaceutical compositions that are used to prepare the synergistic formulation.

ARP960102562A 1995-05-26 1996-05-14 SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT. AR003951A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists

Publications (1)

Publication Number Publication Date
AR003951A1 true AR003951A1 (en) 1998-09-30

Family

ID=47225806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102562A AR003951A1 (en) 1995-05-26 1996-05-14 SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT.

Country Status (4)

Country Link
KR (1) KR960040360A (en)
AR (1) AR003951A1 (en)
MY (1) MY118944A (en)
PE (1) PE54697A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519875A (en) * 2003-03-06 2006-08-31 セルジーン・コーポレーション Selective cytokine inhibitors for treating central nervous system disorders

Also Published As

Publication number Publication date
MY118944A (en) 2005-02-28
KR960040360A (en) 1996-12-17
PE54697A1 (en) 1998-01-06

Similar Documents

Publication Publication Date Title
CO4700422A1 (en) PHARMACEUTICAL PRODUCT COMPRISING A SYNERGIC AMOUNT OF A SELECTIVE NMDA ANTAGONIST OF THE PREVIOUS BRAIN AND A COMPOUND CAPABLE OF INCREASING THE EXCITING FEEDBACK OF A TALAMO VENTRAL NUCLEUM FOR TREATMENT
DE60134453D1 (en) Pharmaceutical compositions for the treatment of CNS and other diseases
BR0116001A (en) Methods for treating neuropsychiatric disorders with nmda receptor antagonists
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
BR0207802A (en) Use of inverse gabaa agonists in combination with nicotine receptor partial agonists, estrogens, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders.
BR9509808A (en) Freeze-dried dosage form for oral administration and process for treating a mammal
ES2196361T3 (en) THERAPEUTIC COMBINATIONS OF RAR ANTAGONISTS AND RXR AGONISTS.
BRPI0412919A (en) combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders
EP1745797A3 (en) Vascularization inhibitors
IT1282736B1 (en) USE OF P-AMINOPHENOL DERIVATIVES TO PREPARE PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
ATE469907T1 (en) TRIPTOLIDE ANALOGUES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATION
NO20021625L (en) Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue
AR003951A1 (en) SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT.
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
Zuchora et al. Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice
DE69124380D1 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT BY T-CELL-MEDIATED DISEASES
DE60004093D1 (en) PHARMACEUTICAL COMPOSITION WHICH CONTAINS RILUZOL AND GABAPENTIN FOR THE TREATMENT OF MOTONEURONAL DISEASES
DK0425109T3 (en) 3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
ECSP961743A (en) COMBINATIONS OF NMDA ANTAGONISTS OF SUB-TYPE NR2B AND DOPAMINE AGONISTS
AR018825A1 (en) ANTIGONISTS OF THE NON-PEPTIDIC BRADIQUININE RECEPTOR FOR USE IN THE TREATMENT OF DISORDERS AND OPHTHALMIC DISEASES
Kovshar The use of medical ozone for prevention of post-operative hypersensitivity during the esthetic prosthetics with veneer application
VILELA-GOULART et al. VERAPAMIL INDUCES DENTAL CARIES AND INHIBITION OF ALKALINE PHOSPHATASE IN RAT
BR9609868A (en) Synthetic conjugate of a protein and a plurality of epitopes for use in medical processes to prevent rejection of a xenograft or at least reduce the extent or rate of rejection to treat a disease and blood removed from a blood donor blood device pharmaceutically acceptable composition use of a conjugate
ECSP961742A (en) SPECIFIC LEAGUES OF NEUROPEPTIDE Y1

Legal Events

Date Code Title Description
FB Suspension of granting procedure